Cerebral small vessel disease and cognition in older adults across the neurodegenerative spectrum: insights from the COMPASS‐ND study
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71546 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Dylan X Guan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Cerebral Small Vessel Diseases, Neurodegenerative Diseases, Cognition, Cognitive Dysfunction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vascular Training Platform (VAST), UK National Institute for Health and Care Research Exeter Biomedical Research Centre, Heart and Stroke Foundation of Canada.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
INTRODUCTION Imaging‐based cerebral small vessel disease (CSVD) summary scores quantify CSVD burden. This study characterized CSVD scores and assessed their cognitive associations in older adults with various neurodegenerative diseases and cognitive profiles. METHODS Baseline data from 958 Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS‐ND) study participants were analyzed (19.4% cognitively normal, 14.9% subjective cognitive decline, 40.3% mild cognitive impairment, 25.4% dementia). MRI markers of cerebral vascular injury (lacunes, microbleeds, white matter hyperintensities [WMHs], and enlarged perivascular spaces) were visually rated, and a cumulative CSVD score was generated. Cognition was measured using the Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating‐Sum of Boxes (CDR‐SB), and a composite neuropsychological battery test z ‐score. RESULTS Higher CSVD scores were associated with greater Hachinski ischemic scores, poorer MoCA performance, worse CDR‐SB, and lower composite z ‐scores. Associations were strongest for cognitive domains of executive function, attention, and learning. DISCUSSION CSVD burden may further contribute to poorer cognition across neurodegenerative conditions and cognitive profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
- Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
- Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
- O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.
- Department of Psychiatry and the Mathison Centre for Mental Health Research and Education, University of Calgary, Calgary, Alberta, Canada.
ORCID-Profile: Dylan X Guan
Förderung
- Vascular Training Platform (VAST)
- UK National Institute for Health and Care Research Exeter Biomedical Research Centre
- Heart and Stroke Foundation of Canada
- Alberta Innovates
- Gordie Howe CARES
- Alzheimer Society of Canada
- Killam Trusts
- Hotchkiss Brain Institute, University of Calgary
Zitieren
APA
Guan, D. X., Ismail, Z., McLeod, G. A., Marzoughi, S., Smith, E. E., & Ganesh, A. (2026). Cerebral small vessel disease and cognition in older adults across the neurodegenerative spectrum: insights from the COMPASS‐ND study. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71546
Vancouver
Guan DX, Ismail Z, McLeod GA, Marzoughi S, Smith EE, Ganesh A. Cerebral small vessel disease and cognition in older adults across the neurodegenerative spectrum: insights from the COMPASS‐ND study. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71546
BibTeX
@article{Guan2026,
author = {Guan, Dylan X and Ismail, Zahinoor and McLeod, Graham A and Marzoughi, Shahab and Smith, Eric E and Ganesh, Aravind},
title = {Cerebral small vessel disease and cognition in older adults across the neurodegenerative spectrum: insights from the COMPASS‐ND study},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71546}
}
EUVIMED